FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383710837> ?p ?o ?g. }

• W4383710837 endingPage "824" @default.
• W4383710837 startingPage "824" @default.
• W4383710837 abstract "Importance It is unknown whether intravenous thrombolysis using tenecteplase is noninferior or preferable compared with alteplase for patients with acute ischemic stroke. Objective To examine the safety and efficacy of tenecteplase compared to alteplase among patients with large vessel occlusion (LVO) stroke. Design, Setting, and Participants This was a prespecified analysis of the Intravenous Tenecteplase Compared With Alteplase for Acute Ischaemic Stroke in Canada (ACT) randomized clinical trial that enrolled patients from 22 primary and comprehensive stroke centers across Canada between December 10, 2019, and January 25, 2022. Patients 18 years and older with a disabling ischemic stroke within 4.5 hours of symptom onset were randomly assigned (1:1) to either intravenous tenecteplase or alteplase and were monitored for up to 120 days. Patients with baseline intracranial internal carotid artery (ICA), M1-middle cerebral artery (MCA), M2-MCA, and basilar occlusions were included in this analysis. A total of 1600 patients were enrolled, and 23 withdrew consent. Exposures Intravenous tenecteplase (0.25 mg/kg) vs intravenous alteplase (0.9 mg/kg). Main Outcomes and Measures The primary outcome was the proportion of modified Rankin scale (mRS) score 0-1 at 90 days. Secondary outcomes were an mRS score from 0 to 2, mortality, and symptomatic intracerebral hemorrhage. Angiographic outcomes were successful reperfusion (extended Thrombolysis in Cerebral Infarction scale score 2b-3) on first and final angiographic acquisitions. Multivariable analyses (adjusting for age, sex, National Institute of Health Stroke Scale score, onset-to-needle time, and occlusion location) were carried out. Results Among 1577 patients, 520 (33.0%) had LVO (median [IQR] age, 74 [64-83] years; 283 [54.4%] women): 135 (26.0%) with ICA occlusion, 237 (45.6%) with M1-MCA, 117 (22.5%) with M2-MCA, and 31 (6.0%) with basilar occlusions. The primary outcome (mRS score 0-1) was achieved in 86 participants (32.7%) in the tenecteplase group vs 76 (29.6%) in the alteplase group. Rates of mRS 0-2 (129 [49.0%] vs 131 [51.0%]), symptomatic intracerebral hemorrhage (16 [6.1%] vs 11 [4.3%]), and mortality (19.9% vs 18.1%) were similar in the tenecteplase and alteplase groups, respectively. No difference was noted in successful reperfusion rates in the first (19 [9.2%] vs 21 [10.5%]) and final angiogram (174 [84.5%] vs 177 [88.9%]) among 405 patients who underwent thrombectomy. Conclusions and Relevance The findings in this study indicate that intravenous tenecteplase conferred similar reperfusion, safety, and functional outcomes compared to alteplase among patients with LVO." @default.
• W4383710837 created "2023-07-11" @default.
• W4383710837 creator A5000954590 @default.
• W4383710837 creator A5004912020 @default.
• W4383710837 creator A5005293237 @default.
• W4383710837 creator A5005997552 @default.
• W4383710837 creator A5009014309 @default.
• W4383710837 creator A5010855646 @default.
• W4383710837 creator A5011932352 @default.
• W4383710837 creator A5012894644 @default.
• W4383710837 creator A5013763830 @default.
• W4383710837 creator A5014648767 @default.
• W4383710837 creator A5014742597 @default.
• W4383710837 creator A5016249935 @default.
• W4383710837 creator A5022381205 @default.
• W4383710837 creator A5039432888 @default.
• W4383710837 creator A5044371836 @default.
• W4383710837 creator A5050811879 @default.
• W4383710837 creator A5054787072 @default.
• W4383710837 creator A5056588732 @default.
• W4383710837 creator A5060044340 @default.
• W4383710837 creator A5061462566 @default.
• W4383710837 creator A5062203257 @default.
• W4383710837 creator A5063701582 @default.
• W4383710837 creator A5064421474 @default.
• W4383710837 creator A5070359183 @default.
• W4383710837 creator A5072926491 @default.
• W4383710837 creator A5072978528 @default.
• W4383710837 creator A5075596562 @default.
• W4383710837 creator A5080305729 @default.
• W4383710837 creator A5080971882 @default.
• W4383710837 creator A5081087159 @default.
• W4383710837 creator A5082918241 @default.
• W4383710837 creator A5084100416 @default.
• W4383710837 creator A5090460265 @default.
• W4383710837 creator A5091249334 @default.
• W4383710837 date "2023-08-01" @default.
• W4383710837 modified "2023-10-18" @default.
• W4383710837 title "Safety and Efficacy of Tenecteplase Compared With Alteplase in Patients With Large Vessel Occlusion Stroke" @default.
• W4383710837 cites W2092739280 @default.
• W4383710837 cites W2117855158 @default.
• W4383710837 cites W2120778013 @default.
• W4383710837 cites W2165568749 @default.
• W4383710837 cites W2475295594 @default.
• W4383710837 cites W2740053016 @default.
• W4383710837 cites W2802880180 @default.
• W4383710837 cites W2884797508 @default.
• W4383710837 cites W2890223142 @default.
• W4383710837 cites W2890910536 @default.
• W4383710837 cites W2905585525 @default.
• W4383710837 cites W2982303713 @default.
• W4383710837 cites W3107450239 @default.
• W4383710837 cites W3111118376 @default.
• W4383710837 cites W3197516697 @default.
• W4383710837 cites W3205262398 @default.
• W4383710837 cites W3214595370 @default.
• W4383710837 cites W4220676728 @default.
• W4383710837 cites W4220994439 @default.
• W4383710837 cites W4225262207 @default.
• W4383710837 cites W4226441491 @default.
• W4383710837 cites W4281290631 @default.
• W4383710837 cites W4283798291 @default.
• W4383710837 cites W4286489470 @default.
• W4383710837 cites W4296794280 @default.
• W4383710837 cites W4307201563 @default.
• W4383710837 cites W4310457222 @default.
• W4383710837 cites W4321849300 @default.
• W4383710837 doi "https://doi.org/10.1001/jamaneurol.2023.2094" @default.
• W4383710837 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37428494" @default.
• W4383710837 hasPublicationYear "2023" @default.
• W4383710837 type Work @default.
• W4383710837 citedByCount "3" @default.
• W4383710837 countsByYear W43837108372023 @default.
• W4383710837 crossrefType "journal-article" @default.
• W4383710837 hasAuthorship W4383710837A5000954590 @default.
• W4383710837 hasAuthorship W4383710837A5004912020 @default.
• W4383710837 hasAuthorship W4383710837A5005293237 @default.
• W4383710837 hasAuthorship W4383710837A5005997552 @default.
• W4383710837 hasAuthorship W4383710837A5009014309 @default.
• W4383710837 hasAuthorship W4383710837A5010855646 @default.
• W4383710837 hasAuthorship W4383710837A5011932352 @default.
• W4383710837 hasAuthorship W4383710837A5012894644 @default.
• W4383710837 hasAuthorship W4383710837A5013763830 @default.
• W4383710837 hasAuthorship W4383710837A5014648767 @default.
• W4383710837 hasAuthorship W4383710837A5014742597 @default.
• W4383710837 hasAuthorship W4383710837A5016249935 @default.
• W4383710837 hasAuthorship W4383710837A5022381205 @default.
• W4383710837 hasAuthorship W4383710837A5039432888 @default.
• W4383710837 hasAuthorship W4383710837A5044371836 @default.
• W4383710837 hasAuthorship W4383710837A5050811879 @default.
• W4383710837 hasAuthorship W4383710837A5054787072 @default.
• W4383710837 hasAuthorship W4383710837A5056588732 @default.
• W4383710837 hasAuthorship W4383710837A5060044340 @default.
• W4383710837 hasAuthorship W4383710837A5061462566 @default.
• W4383710837 hasAuthorship W4383710837A5062203257 @default.
• W4383710837 hasAuthorship W4383710837A5063701582 @default.
• W4383710837 hasAuthorship W4383710837A5064421474 @default.
• W4383710837 hasAuthorship W4383710837A5070359183 @default.

• next